Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125394802 | 12539480 | 2 | F | 20160727 | 20160708 | 20160803 | EXP | JP-OTSUKA-2016_016331 | OTSUKA | 0.00 | Y | 0.00000 | 20160803 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125394802 | 12539480 | 1 | PS | ABILIFY MAINTENA | ARIPIPRAZOLE | 1 | Intramuscular | UNK, ONCE IN FOUR WEEKS | U | 202971 | SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE | ||||||||
| 125394802 | 12539480 | 2 | SS | ATORVASTATIN | ATORVASTATIN | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125394802 | 12539480 | 1 | Product used for unknown indication |
| 125394802 | 12539480 | 2 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125394802 | 12539480 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125394802 | 12539480 | Blood creatine phosphokinase increased | |
| 125394802 | 12539480 | Liver function test increased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125394802 | 12539480 | 1 | 20150716 | 20160706 | 0 | |
| 125394802 | 12539480 | 2 | 20160226 | 20160608 | 0 |